Income statement
USD
Annual
| Metric | 2024 |
|---|---|
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -112M |
| EBITDA | -112M |
| Net Income | -94M |
| EPS (Diluted) | — |
Healthcare
Live Price
Offline$8.54
-6.97% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Catabasis Pharmaceuticals, Inc. (CATB) is a Healthcare stock with a market cap of $234.86M. The stock last traded around $8.54. Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin -15144.3% and ROIC -42.8%. Valuation already assumes a fairly strong business story at price/sales 332.7. Stock Foundry combines CATB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CATB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CATB Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CATB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$94.3M
Free Cash Flow
-$81.5M
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
0.0%
Net Margin
-13938.2%
Income statement
USD
| Metric | 2024 |
|---|---|
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -112M |
| EBITDA | -112M |
| Net Income | -94M |
| EPS (Diluted) | — |
Balance sheet
USD
| Metric | 2024 |
|---|---|
| Cash & Equivalents | 60M |
| Total Assets | 342M |
| Total Liabilities | 23M |
| Shareholder Equity | 319M |
| Total Debt | 5M |
| Net Debt | -54M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
81M
Capital Expenditures
325K
Free Cash Flow
82M
Key ratios
Gross Margin
0.0%
Operating Margin
-15144.3%
Net Margin
-13938.2%
ROE
-35.7%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.